A study from the Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, School of Medicine, University of California, San Diego, Gilman Drive, La Jolla, CA 92093-0723, USA shows that “Interleukin-17 receptor a signaling in transformed enterocytes promotes …tumorigenesis.” This study was published in the 14 December 2014 issue of Immunity by Prof Michael Karin, Dr. Wang K, and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based therapy for Cancer: Interleukin-27 (IL-27) suppresses intestinal tumorigenesis via inhibition of IL-17-mediated oncogenic signalling. Thus, pharmacological formulations encompassing ” IL-27 activators” may be used to inhibit intestinal cancer.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Interleukin-based therapy for Cancer: Interleukin-27 (IL-27) suppresses intestinal tumorigenesis via inhibition of IL-17-mediated oncogenic signalling, 11/March/2015, 15.33, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation